Organon & Co.
OGNOrganon & Co. (OGN) is a global healthcare company specializing in the development and commercialization of pharmaceutical and biosimilar products. It focuses on women’s health, reproductive rights, and other therapeutic areas, aiming to improve health outcomes through innovative medicines. The company was spun off from Merck & Co. in 2021 to concentrate on its dedicated portfolio of women’s health, biosimilars, and other biopharmaceuticals.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 11, 2025 | $0.02 | 2025-11-20 | 2025-11-20 |
| September 11, 2025 | $0.02 | 2025-08-15 | 2025-08-15 |
| June 12, 2025 | $0.02 | 2025-05-12 | 2025-05-12 |
| March 13, 2025 | $0.28 | 2025-02-24 | 2025-02-24 |
| December 12, 2024 | $0.28 | 2024-11-12 | 2024-11-12 |
Dividends Summary
- Consistent Payer: Organon & Co. has rewarded shareholders with 18 dividend payments over the past 4 years.
- Total Returned Value: Investors who held OGN shares during this period received a total of $4.26 per share in dividend income.
- Latest Payout: The most recent dividend of $0.02/share was paid 43 days ago, on December 11, 2025.
- Yield & Schedule: OGN currently pays dividends quarterly with an annual yield of 3.49%.
- Dividend Growth: Since 2021, the dividend payout has decreased by 92.9%, from $0.28 to $0.02.
Company News
Sun Pharmaceutical Industries is reportedly evaluating a potential acquisition of Organon & Co, a U.S.-based women's healthcare company, in what could be India's largest cross-border pharma deal. Sun Pharma has submitted a non-binding all-cash bid with $10-14 billion in acquisition financing arranged. The deal, valued at approximately $10 billion...
The inaugural National Women's Health Summit will take place in Toronto on March 24-25, 2026, bringing together health researchers, clinicians, and advocates to discuss critical women's health issues and potential innovations.
A national women's health summit will be held in Toronto on March 24-25, 2026, bringing together researchers, clinicians, and health advocates to discuss critical women's health issues and drive meaningful change.
The global contraceptive devices market is projected to grow from $20 billion in 2024 to $33 billion by 2032, driven by increased awareness, technological innovations, and changing demographic trends.
A new McKinsey Health Institute report reveals that Canadian women spend 24% more time in poor health than men, potentially costing the economy $37 billion annually by 2040. Women's Health Collective Canada advocates for increased investment in women's health research and care.
